Indian Institute of Technology Madras, Bhupat and Jyoti Mehta School of Biosciences, Department of Biotechnology, Chennai, 600036, India.
Vels University, Department of Biotechnology, Chennai, 600117, India.
Sci Rep. 2018 Aug 20;8(1):12439. doi: 10.1038/s41598-018-30772-4.
Mesenchymal stem cells (MSCs) have immense potential for cell-based therapy of acute and chronic pathological conditions. MSC transplantation for cell-based therapy requires a substantial number of cells in the range of 0.5-2.5 × 10 cells/kg body weight of an individual. A prolific source of MSCs followed by in vitro propagation is therefore an absolute prerequisite for clinical applications. Umbilical cord tissue (UCT) is an abundantly available prolific source of MSC that are fetal in nature and have higher potential for ex-vivo expansion. However, the ex-vivo expansion of MSCs using a xenogeneic supplement such as fetal bovine serum (FBS) carries the risk of transmission of zoonotic infections and immunological reactions. We used platelet lysate (PL) as a xeno-free, allogeneic replacement for FBS and compared the biological and functional characteristics of MSC processed and expanded with PL and FBS by explant and enzymatic method. UCT-MSCs expanded using PL displayed typical immunophenotype, plasticity, immunomodulatory property and chromosomal stability. PL supplementation also showed 2-fold increase in MSC yield from explant culture with improved immunomodulatory activity as compared to enzymatically dissociated cultures. In conclusion, PL from expired platelets is a viable alternative to FBS for generating clinically relevant numbers of MSC from explant cultures over enzymatic method.
间充质干细胞(MSCs)在急性和慢性病理条件的基于细胞的治疗中有巨大的潜力。基于细胞的治疗的 MSC 移植需要相当数量的细胞,范围为 0.5-2.5×个体体重的 10 细胞/kg。因此,丰富的 MSC 来源和体外增殖是临床应用的绝对前提。脐带组织(UCT)是 MSC 的丰富来源,这些 MSC 本质上是胎儿来源的,具有更高的体外扩增潜力。然而,使用胎牛血清(FBS)等异种补充剂体外扩增 MSC 存在传播人畜共患病感染和免疫反应的风险。我们使用血小板裂解液(PL)作为 FBS 的无动物来源的同种替代物,并通过组织块和酶消化法比较了用 PL 和 FBS 处理和扩增的 MSC 的生物学和功能特性。使用 PL 扩增的 UCT-MSCs 显示出典型的免疫表型、可塑性、免疫调节特性和染色体稳定性。与酶消化培养物相比,PL 补充物还使组织块培养物中 MSC 的产量增加了 2 倍,并且具有更好的免疫调节活性。总之,来自过期血小板的 PL 是 FBS 的可行替代品,可通过组织块培养而不是酶消化法从 UCT 中产生临床相关数量的 MSC。